TrialCurveNETTER-2: reconstructed Kaplan–Meier curves
[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | eClinicalMedicine. 2026 Aug 7;98:104109. doi: 10.1016/j.eclinm.2026.104109 |
|---|---|
| DOI | 10.1016/j.eclinm.2026.104109 |
| Registry | NCT03972488 |
| Phase | Phase 3 |
| Conditions | Gastro-enteropancreatic Neuroendocrine Tumor |
| Interventions | Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable |
| Sponsor | Advanced Accelerator Applications |
| Enrolment | 226 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Grade 2 NETs
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 177Lu-DOTATATE arm 28.9 months; Control arm 13.8 months. Survival at 12 months: 177Lu-DOTATATE arm 87%; Control arm 55%. Hazard ratio 177Lu-DOTATATE arm vs Control arm 0.32 (95% CI 0.18–0.55).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| 177Lu-DOTATATE arm | 99 | 29 | 28.9 |
| Control arm | 48 | 25 | 13.8 |
- 177Lu-DOTATATE arm vs Control arm: reconstructed HR 0.32 (95% CI 0.18–0.55)
Landmark survival (reconstructed)
| Time | 177Lu-DOTATATE arm | Control arm |
|---|---|---|
| 6 mo | 96.8% | 76.3% |
| 12 mo | 86.8% | 55.4% |
| 18 mo | 75.7% | 41.3% |
| 24 mo | 56.7% | 27.5% |
Checks against the published figure
- 177Lu-DOTATATE arm median: printed 29, reconstructed 28.9 pass
- Control arm median: printed 13.8, reconstructed 13.8 pass
- hazard ratio: printed 0.306, reconstructed 0.319 pass
Progression-free survival — Grade 3 NETs
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 177Lu-DOTATATE arm 22.3 months; Control arm 5.6 months. Survival at 12 months: 177Lu-DOTATATE arm 68%; Control arm 22%. Hazard ratio 177Lu-DOTATATE arm vs Control arm 0.26 (95% CI 0.14–0.48).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| 177Lu-DOTATATE arm | 52 | 27 | 22.3 |
| Control arm | 27 | 21 | 5.6 |
- 177Lu-DOTATATE arm vs Control arm: reconstructed HR 0.26 (95% CI 0.14–0.48)
Landmark survival (reconstructed)
| Time | 177Lu-DOTATATE arm | Control arm |
|---|---|---|
| 6 mo | 84.6% | 43.5% |
| 12 mo | 68.3% | 21.7% |
| 18 mo | 52.5% | — |
| 24 mo | 42.0% | — |
Checks against the published figure
- 177Lu-DOTATATE arm median: printed 22.2, reconstructed 22.3 pass
- Control arm median: printed 5.6, reconstructed 5.63 pass
- hazard ratio: printed 0.266, reconstructed 0.263 pass
Progression-free survival — Pancreatic NETs
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 177Lu-DOTATATE arm 19.4 months; Control arm 8.5 months. Survival at 12 months: 177Lu-DOTATATE arm 76%; Control arm 39%. Hazard ratio 177Lu-DOTATATE arm vs Control arm 0.32 (95% CI 0.19–0.54).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| 177Lu-DOTATATE arm | 82 | 39 | 19.4 |
| Control arm | 41 | 28 | 8.5 |
- 177Lu-DOTATATE arm vs Control arm: reconstructed HR 0.32 (95% CI 0.19–0.54)
Landmark survival (reconstructed)
| Time | 177Lu-DOTATATE arm | Control arm |
|---|---|---|
| 6 mo | 91.2% | 63.1% |
| 12 mo | 76.4% | 39.1% |
| 18 mo | 55.6% | 26.4% |
| 24 mo | 38.3% | — |
Checks against the published figure
- 177Lu-DOTATATE arm median: printed 19.4, reconstructed 19.4 pass
- Control arm median: printed 8.5, reconstructed 8.45 pass
- hazard ratio: printed 0.336, reconstructed 0.321 pass
Progression-free survival — Gastrointestinal NETs
From figure panel D · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 177Lu-DOTATATE arm not reached; Control arm 8.6 months. Survival at 12 months: 177Lu-DOTATATE arm 86%; Control arm 48%. Hazard ratio 177Lu-DOTATATE arm vs Control arm 0.23 (95% CI 0.12–0.47).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| 177Lu-DOTATATE arm | 69 | 16 | not reached |
| Control arm | 34 | 18 | 8.6 |
- 177Lu-DOTATATE arm vs Control arm: reconstructed HR 0.23 (95% CI 0.12–0.47)
Landmark survival (reconstructed)
| Time | 177Lu-DOTATATE arm | Control arm |
|---|---|---|
| 6 mo | 93.8% | 66.9% |
| 12 mo | 86.5% | 48.3% |
| 18 mo | 81.7% | 32.2% |
| 24 mo | 66.3% | 25.8% |
Checks against the published figure
- Control arm median: printed 8.7, reconstructed 8.62 pass
- hazard ratio: printed 0.233, reconstructed 0.233 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials